O'Reilly Aine, Larkin James
a Department of Renal and Melanoma , Royal Marsden Hospital , London , United Kingdom of Great Britain and Northern Ireland.
Expert Opin Drug Saf. 2017 Aug;16(8):955-961. doi: 10.1080/14740338.2017.1351537. Epub 2017 Jul 18.
Nivolumab, a human IgG4 monoclonal antibody directed against PD-1, is a checkpoint inhibitor that is licenced in the treatment of metastatic melanoma either as a monotherapy or in combination with ipilimumab, a CTLA-4 inhibitor. The introduction of immune checkpoint inhibitors to the therapeutic landscape has dramatically altered outcomes in a proportion of patients with metastatic melanoma. Immune checkpoint inhibitors result in a toxicity profile that is distinct from that of chemotherapy or targeted therapy based on their immunomodulatory mechanism and similarly can result in patterns of response that are unique. Areas covered: Herein we will profile nivolumab's efficacy and safety both as a combination therapy and a monotherapy and discuss the results of relevant clinical trials in this respect. Expert opinion: The future of immunotherapy in melanoma will evolve around the development of biomarkers, the refinement of criteria to define patterns of response and toxicity and the combination of current immunotherapies with existing and novel agents to maximise responses.
纳武单抗是一种针对程序性死亡受体1（PD-1）的人IgG4单克隆抗体，是一种检查点抑制剂，已被批准用于治疗转移性黑色素瘤，可单药治疗或与细胞毒性T淋巴细胞相关抗原4（CTLA-4）抑制剂伊匹单抗联合使用。免疫检查点抑制剂引入治疗领域后，显著改变了部分转移性黑色素瘤患者的治疗结果。基于其免疫调节机制，免疫检查点抑制剂产生的毒性特征与化疗或靶向治疗不同，同样也能产生独特的反应模式。涵盖领域：在此，我们将概述纳武单抗作为联合疗法和单药疗法的疗效和安全性，并讨论这方面相关临床试验的结果。专家观点：黑色素瘤免疫治疗的未来将围绕生物标志物的开发、定义反应和毒性模式标准的完善，以及将当前免疫疗法与现有和新型药物联合使用以最大化反应展开。
